Array BioPharma, Inc. (ARRY)
-NasdaqGM | Prev Close: | 5.66 |
|---|
| Open: | N/A |
|---|
| Bid: | 5.62 x 400 |
|---|
| Ask: | 5.79 x 400 |
|---|
| 1y Target Est: | 6.42 |
|---|
| Beta: | 1.73 |
|---|
| Next Earnings Date: | 12-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 3.00 - 6.56 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,120,350 |
|---|
| Market Cap: | 660.95M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.52 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Array BioPharma's CEO Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)at Seeking Alpha(Thu, May 16)
- AstraZeneca Advances Three Cancer Drugs Into Late-Stage Trialsat Bloomberg(Thu, May 16)
- Part 3: Will Array BioPharma Become A Late Stage Biopharmaceutical Company?at Seeking Alpha(Thu, May 16)
- Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual MeetingPR Newswire(Wed, May 15)
- Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stockat Seeking Alpha(Wed, May 15)
- ARRAY BIOPHARMA INC FinancialsEDGAR Online Financials(Tue, May 14)
- Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?at Seeking Alpha(Sun, May 12)
- Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?at Seeking Alpha(Sun, May 12)
- Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare ConferencePR Newswire(Wed, May 8)
- Array BioPharma's CEO Discusses Q3 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- ARRAY BIOPHARMA INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 7)
- Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buyat Seeking Alpha(Tue, May 7)
- Array BioPharma Inc. Earnings Call scheduled for 9:00 am ET todayCCBN(Tue, May 7)
- Array BioPharma Earnings: Here’s Why Shares are Up Nowat Wall St. Cheat Sheet(Mon, May 6)
- Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013PR Newswire(Mon, May 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 10.20 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.55 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.13 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -1.07 |
|---|
Business Summary
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the A...
View More